 A new Alzheimer's treatment has been approved by the FDA. CBS News chief medical correspondent Dr. John LaPook explains. Denonimab is the second drug available for Alzheimer's patients with early symptoms. It will be sold under the brand name Kesunla. And it slowed cognitive decline overall by about 22% over 18 months. Now, it did not reverse the decline. But this is still exciting to me because previous trials over the years that have tried removing amyloid from the brain have not worked.